Overview


According to FutureWise analysis the market for outsourced clinical trials and formulation in 2023 is US$ 15.2 billion, and is expected to reach US$ 25.97 billion by 2031 at a CAGR of 6.9%.

Clinical trials are research studies conducted on people with the goal of testing a medical, surgical, or behavioural intervention. Researchers must first determine whether a novel treatment, such as a new drug or diet, or a medical equipment (such as a pacemaker), is safe and effective when used in humans. In addition to discovering new treatments, clinical trials are used to evaluate the effectiveness of a novel treatment to a standard one. Clinical trials are also used to test new methods for diagnosing diseases early on, frequently before symptoms develop. Clinical trials are also used to examine whether there are any answers to a health concern that may be avoided. Furthermore, technological improvements in implantable insulin pumps, an increase in the incidence of chronic conditions such as obesity and heart disease, and an increase in demand for home-based therapies The market for diabetes management and counselling is growing. Furthermore, an increase in the elderly population, combined with an increase in diabetes prevalence, favourable reimbursement policies in the healthcare system, and a surge in R D activities aimed at developing novel implantable insulin pump technologies, all contribute to the market's growth. Government regulations, on the other hand, are likely to stifle market expansion during the projection period.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Outsourced Clinical Trials and Formulation Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Outsourced Clinical Trials and Formulation Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Thermo Fisher Scientific Inc. (Patheon)
  • Piramal Pharma Solutions
  • BioXcellence (Boehringer Ingelheim International GmbH)
  • Siegfried Holding AG
  • Evotec A.G.
  • Ascendia Pharmaceuticals
  • Experic Services
  • Quotient Sciences
  • Velesco Pharmaceutical Services, Inc.
  • Elements Group (Avomeen)
  • VxP Pharma
  • Adare Pharmaceuticals, Inc.
  • KP Pharmaceutical Technology Inc.
  • Enteris Biopharma, Inc.
  • Aenova Holding GmbH
  • Ardena Holding NV
  • Pharmaceutics International, Inc.
  • Alcami Corporation, Inc.
  • NextPharma Technologies
  • Corden Pharma International GmbH
  • Corerx, Inc.
  • Recipharm AB
  • Pace Analytical Services, LLC
  • Almac Group, Inc.
  • Cambrex Corporation

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product

  • Oral dosage Forms
    • Solid dosage Forms
    • Liquid Dosage Forms
    • Semi-solid Dosage Forms
  • Injectable Dosage Forms
  • Others

By Application

  • API Manufacturing
  • Fill-Finish Product Manufacturing
  • Drug Product Development
  • Packaging/labelling
  • Others

By End User

  • Big Pharmaceutical /Biotech Companies
  • Small and Medium Size Pharma/Biotech Companies
  • Emerging/virtual Pharma Companies
  • Nutraceutical Companies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Outsourced Clinical Trials and Formulation Market By Product, By Application, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Outsourced Clinical Trials and Formulation Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Outsourced Clinical Trials and Formulation Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Outsourced Clinical Trials and Formulation Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Outsourced Clinical Trials and Formulation Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral dosage Forms
         1.1. Solid dosage Forms
         1.2. Liquid Dosage Forms
         1.3. Semi-solid Dosage Forms
        2. Injectable Dosage Forms
        3. Others

  • 8.   Outsourced Clinical Trials and Formulation Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. API Manufacturing
        2. Fill-Finish Product Manufacturing
        3. Drug Product Development
        4. Packaging / labeling
        5. Others

  • 9.   Outsourced Clinical Trials and Formulation Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Big Pharmaceutical /Biotech Companies
        2. Small and Medium Size Pharma/Biotech Companies
        3. Emerging/virtual Pharma Companies
        4. Nutraceutical Companies

  • 10.   North America Outsourced Clinical Trials and Formulation Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Outsourced Clinical Trials and Formulation Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Outsourced Clinical Trials and Formulation Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Outsourced Clinical Trials and Formulation Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Thermo Fisher Scientific Inc. (Patheon)
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Piramal Pharma Solutions
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. BioXcellence (Boehringer Ingelheim International GmbH)
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Siegfried Holding AG
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Evotec A.G.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Ascendia Pharmaceuticals
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Experic Services
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Quotient Sciences
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Velesco Pharmaceutical Services, Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Elements Group (Avomeen)
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. VxP Pharma
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Adare Pharmaceuticals, Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. KP Pharmaceutical Technology Inc.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Enteris Biopharma, Inc.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Aenova Holding GmbH
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Ardena Holding NV
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Pharmaceutics International, Inc.
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Alcami Corporation, Inc.
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. NextPharma Technologies
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. Corden Pharma International GmbH
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview
        21. Corerx, Inc.
         21.1. Company Overview
         21.2. Product Portfolio
         21.3. SWOT Analysis
         21.4. Financial Overview
         21.5. Strategic Overview
        22. Recipharm AB
         22.1. Company Overview
         22.2. Product Portfolio
         22.3. SWOT Analysis
         22.4. Financial Overview
         22.5. Strategic Overview
        23. Pace Analytical Services, LLC
          23.1. Company Overview
          23.2. Product Portfolio
          23.3. SWOT Analysis
          23.4. Financial Overview
          23.5. Strategic Overview
        24. Almac Group, Inc.
         24.1. Company Overview
          24.2. Product Portfolio
         24.3. SWOT Analysis
         24.4. Financial Overview
         24.5. Strategic Overview
        25. Cambrex Corporation
         25.1. Company Overview
         25.2. Product Portfolio
         25.3. SWOT Analysis
         25.4. Financial Overview
         25.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients